Good morning, everyone, and how are you today? We are doing just fine, thank you, especially since the Pharmalot campus is unusually quiet. A short person is sleeping in and the official mascot is snoozing happily in a corner. This leaves us to the matter at hand, which is foraging for items of interest. On that note, please enjoy the tidbits assembled here and, if you choose to do so, join us for a quick cup of stimulation. Our flavor today is hot-buttered rum, for those who care. Meanwhile, have a smashing day and please do keep in touch. …

The Food and Drug Administration approved a new tuberculosis medicine that shortens and improves treatment for the hardest-to-treat cases, the Associated Press explains. This is the first TB drug from a nonprofit group. The TB Alliance developed pretomanid with help from charities and government agencies. The pill was approved for use with two other antibiotics. Decades of incomplete or ineffective treatment have resulted in TB strains that are drug-resistant and not killed by standard medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe for the uninformed, which included myself, East Greenbush NY is what most of us call the Rensselaer site of Regeneron.

Your daily dose of news in health and medicine

Privacy Policy